Cargando…
Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions
Using a genome-wide CRISPR screen, we identified CDK9, DHODH, and PRMT5 as synthetic lethal partners with gilteritinib treatment in fms-like tyrosine kinase 3 (FLT3)–internal tandem duplication (ITD) acute myeloid leukemia (AML) and genetically and pharmacologically validated their roles in gilterit...
Autores principales: | Zhang, Pu, Brinton, Lindsey T., Gharghabi, Mehdi, Sher, Steven, Williams, Katie, Cannon, Matthew, Walker, Janek S., Canfield, Daniel, Beaver, Larry, Cempre, Casey B., Phillips, Hannah, Chen, Xuyong, Yan, Pearlly, Lehman, Amy, Scherle, Peggy, Wang, Min, Vaddi, Kris, Baiocchi, Robert, Wang, Ruoning, Sampath, Deepa, Alinari, Lapo, Blachly, James S., Lapalombella, Rosa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481139/ https://www.ncbi.nlm.nih.gov/pubmed/36112677 http://dx.doi.org/10.1126/sciadv.abp9005 |
Ejemplares similares
-
Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020) -
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020) -
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
por: Hing, Zachary A., et al.
Publicado: (2023) -
P1250: EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA
por: Brown, F., et al.
Publicado: (2022) -
Novel targeted therapies for mantle cell lymphoma
por: Alinari, Lapo, et al.
Publicado: (2012)